# Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye

> **NCT02581891** · PHASE4 · COMPLETED · sponsor: **Bayer** · enrollment: 287 (actual)

## Conditions studied

- Macular Degeneration

## Interventions

- **DRUG:** Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)
- **DRUG:** Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)

## Key facts

- **NCT ID:** NCT02581891
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-19
- **Primary completion:** 2019-04-26
- **Final completion:** 2019-04-26
- **Target enrollment:** 287 (ACTUAL)
- **Last updated:** 2023-11-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02581891

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02581891, "Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02581891. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*